Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774

NCT05691491 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05691491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05691491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 28, 2023
Completion date
March 1, 2027
Enrollment
42 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, advanced microsatellite stable colorectal carcinoma, hematopoietic and lymphatic system neoplasm, metastatic malignant solid neoplasm, metastatic microsatellite stable colorectal carcinoma, stage iii colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8